Navigation Links
AMT Provides Business Update for the Third Quarter 2009
Date:11/18/2009

AMSTERDAM, November 18 /PRNewswire-FirstCall/ --

- Glybera(R) Clinical Data Presented at Meeting of American Heart Association

Amsterdam Molecular Therapeutics (EuroNext Amsterdam: AMT), a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2009.

    Q3 2009 Highlights

    - Jorn Aldag joins AMT as Chief Executive Officer

    - Glybera(R) remains on track for filing for regulatory approval in next
      three months

Jorn Aldag appointed as Chief Executive Officer

On September 24, 2009 AMT announced that Jorn Aldag, previously President and CEO of Evotec AG, Germany, would join AMT as Chief Executive Officer as of October 05, 2009. Jorn Aldag holds business degrees from the European Business School and the Harvard Business School. He remains Chairman of Molecular Partners AG, Switzerland, a privately-held biotech company focused on the development of its proprietary DARPin scaffold technology and its proprietary pipeline. Mr. Aldag's appointment was approved by AMT's Extraordinary General Meeting of shareholders on November 4, 2009.

At the same time, Prof. Sander van Deventer stepped down as interim CEO. He will continue to contribute his expertise and experience to AMT as Chairman of the Scientific Advisory Board and Business Consultant.

Business Update

AMT's cash position(*) on September 30, 2009 amounts to EUR21.4 million compared to EUR25.0 million on June 30, 2009. The cash outflow in the third quarter of 2009, amounting to EUR3.6 million mainly represented operational cash flow and is well within the guidance for this period. The Company is adjusting its guidance for the year-end cash balance to approximately EUR17 milli
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
2. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
3. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
4. Microbix Biosystems Provides a Corporate Update
5. Alexandria Real Estate Equities, Inc. Provides Update
6. SemBioSys provides an update on Botaneco
7. MacuSight(R) Provides Clinical Development Update for Perceiva(TM)
8. New nanostructure technology provides advances in eyeglass, solar energy performance
9. Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
10. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
11. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... 17, 2013  KaloBios Pharmaceuticals, Inc. (Nasdaq: ... R. Joseph as Chief Legal Officer.  Mr. Joseph ... experience and has worked in both public and private ... (Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO ) ... a general counsel and senior executive and his knowledge ...
(Date:6/17/2013)... NEW YORK , June 17, 2013 /PRNewswire-iReach/ -- ... imaging techniques and other studies to explore the neurophysiological ... the impact of life experience such as bullying and ... Ten researchers will present their latest findings at ... in Scottsdale, AZ. More than ...
(Date:6/17/2013)... DUBLIN , June 17, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/9rwvs2/north_america ) has announced the addition of ... Market - by Formulations [Liposomes, Microspheres, & ... Prefilled, Pen, Needle Free & Auto Injectors] ... to their offering. ,      ...
(Date:6/17/2013)... -- The Greater Raleigh Chamber of ... Management, Inc. to its Board of Advisors. "We,re ... Board of Advisors," said Harvey Schmitt , president and ... prestigious positions to hold in the business community. We look ... will contribute." The Board of Advisors is made ...
Breaking Biology Technology:KaloBios Appoints Donald R. Joseph as Chief Legal Officer 2KaloBios Appoints Donald R. Joseph as Chief Legal Officer 3KaloBios Appoints Donald R. Joseph as Chief Legal Officer 4New Research On Stuttering Jul 2-3 At Arizona Symposium 2New Research On Stuttering Jul 2-3 At Arizona Symposium 3North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 2North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 3Raleigh Chamber Names Bob Riedford to Board of Advisors 2
... FRANCISCO, June 13, 2011 San Francisco,s leadership in ... of "BioSF," a public-private partnership to support startup creation ... zone in San Francisco,s Mission Bay. "BioSF ... said San Francisco Mayor Edwin M. Lee. "This innovative ...
... EMERYVILLE, Calif., June 13, 2011 MedeAnalytics, a ... today a report which analyzes the leading healthcare ... accountable care organization (ACO) economic model as presented ... Savings Program. (Logo:   http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ...
... HONG KONG, June 10, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood ... China,s leading provider of cord blood collection, laboratory testing, hematopoietic ... preliminary unaudited financial results for the fourth quarter and fiscal ... Fourth Quarter of Fiscal 2011 Highlights ...
Cached Biology Technology:San Francisco and QB3 Launch BioSF, a Program to Enrich the City's Biotech Industry 2MedeAnalytics Releases Analysis of Public Comments on ACO Proposed Rule 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 10
(Date:6/16/2013)... A mechanism that cells use to group together and move ... been described for the first time by scientists at UCL. ... new study focuses on the process that occurs when cancer ... the body during metastasis. Scientists know that cancer cells recruit ... how this process takes place and how it could be ...
(Date:6/15/2013)... A drug approved in Europe to treat osteoporosis has ... cancer cells, even in cancers that have become resistant ... Institute study. , The findings, presented June 15, 2013, ... indicate that the drug bazedoxifene packs a powerful one-two ... cancer cell growth, but also flags the estrogen receptor ...
(Date:6/14/2013)... researchers from Oklahoma State University, the Samuel Roberts ... advance understanding of how socio-ecological systems can adapt ... the state. , Oklahoma was one of ... Science Foundation Experimental Program to Stimulate Competitive Research ... the next five years. The Oklahoma State ...
Breaking Biology News(10 mins):'Chase and run' cell movement mechanism explains process of metastasis 2Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors 2OU researchers collaborate on $20 million NSF EPSCoR grant 2OU researchers collaborate on $20 million NSF EPSCoR grant 3
... aluminium fibre combination makes them nearly immune to ... developed at Delft University of Technology, will lead ... special material (called CentrAl, an abbreviation of Central ... the development of truly energy-efficient, green aircraft. Lower ...
... 25, 2007) Stem cell therapy for cardiac regeneration ... will be the focus of the keynote addresses at ... of Cardiovascular Disease conference. Conducted by Cedars-Sinai Medical Center ... 5, the conference is co-sponsored by the California Chapter ...
... last spring, the Vanderbilt greenhouse held more members of ... to exist in the wild., This unusual bounty was ... a doctoral student in the biological sciences department, working ... species is called the giant whorled sunflower, Helianthus verticillatus. ...
Cached Biology News:New Delft material concept for aircraft wings could save billions 2Cardiologists and heart surgeons meet for 'Controversies and Advances' conference 2Cardiologists and heart surgeons meet for 'Controversies and Advances' conference 3Student study bolsters case for adding a rare sunflower to the endangered species list 2